Herpes simplex virus and human papillomavirus genital infections: New and investigational therapeutic options

International Journal of Dermatology

Volumn 49, Issue 7, 2010, Pages 733-749

  Viera, Martha H ^a   Amini, Sadegh ^a   Huo, Ran ^a   Konda, Sailesh ^a   Block, Samantha ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2A INTERFERON; CAFFEINE DERIVATIVE; CALCIPOTRIOL; CATECHIN; CIDOFOVIR; CIMETIDINE; FAMCICLOVIR; FLUOROURACIL; FOSCARNET; IDOXURIDINE; IMIQUIMOD; OLIGODEOXYNUCLEOTIDE; PENCICLOVIR; PODOPHYLLIN; PODOPHYLLOTOXIN; PRO 2000; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERFERON; RESIQUIMOD; RETINOID; SINECATECHIN; TRICHLOROACETIC ACID; TROMANTADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VIVAGEL; WART VIRUS VACCINE; ANTIVIRUS AGENT;

ABDOMINAL PAIN; APPLICATION SITE DISCOMFORT; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE ULCER; BONE MARROW SUPPRESSION; BURNING SENSATION; CARBON DIOXIDE LASER; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DESICCATION; DIARRHEA; EPIDERMODYSPLASIA VERRUCIFORMIS; EROSION; EVIDENCE BASED PRACTICE; EXCISION; GENITAL SYSTEM DISEASE; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; IMPETIGO; LIVER DYSFUNCTION; LOW DRUG DOSE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHOTODYNAMIC THERAPY; PREGNANCY; PSYCHOSIS; PULSED DYE LASER; RECURRENT DISEASE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SKIN INDURATION; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VAGINA CANCER; VESICULAR RASH; VOMITING; VULVA CANCER; WART VIRUS; DRUG DESIGN; GENITAL HERPES; IMMUNOLOGY;

ANTIVIRAL AGENTS; CONDYLOMATA ACUMINATA; DRUG DESIGN; HERPES GENITALIS; HUMANS; PAPILLOMAVIRUS INFECTIONS;

EID: 77954147560     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04375.x     Document Type: Review

References (206)

1. Xu F. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
2. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007, 2(Suppl 1):S6-S13.
3. Von Krogh G, Lacey CJ, Gross G. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000, 76:162-168.
4. Thomson JP, Grace RH. The treatment of perianal and anal condylomata acuminata: a new operative technique. J R Soc Med 1978, 71:180-185.
5. Ferenczy A, Behelak Y, Haber G. Treating vaginal and external anogenital condylomas with electrosurgery vs CO2 laser ablation. J Gynecol Surg 1995, 11:41-50. Spring
6. Taner ZM, Taskiran C, Onan AM. Therapeutic value of trichloroacetic acid in the treatment of isolated genital warts on the external female genitalia. J Reprod Med 2007, 52:521-525.
7. Petersen CS, Weismann K. Quercetin and kaempherol: an argument against the use of podophyllin? Genitourin Med 1995, 71:92-93.
8. Leslie KO, Shitamoto B. The bone marrow in systemic podophyllin toxicity. Am J Clin Pathol 1982, 77:478-480.
9. Moher LM, Maurer SA. Podophyllum toxicity: case report and literature review. J Fam Pract 1979, 9:237-240.
10. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007, 67:2187-2210.
11. Arany I, Tyring SK, Brysk MM. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob Agents Chemother 2000, 44:1869-1873.
12. Beutner KR, Tyring SK, Trofatter KF. A Imiquimod, a patient-applied immune response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998, 42:789-794.
13. Handley JM, Horner T, Maw RD. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin Med 1991, 67:297-302.
14. Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts. Int J STD AIDS 2007, 18:365-368.
15. Stefanaki C, Katzouranis I, Lagogianni E. Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. Int J STD AIDS 2008, 19:441-444.
16. Aynaud O, Buffet M, Roman P. Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment. Eur J Dermatol 2008, 18:153-158.
17. Carrozza PM, Merlani GM, Burg G. CO(2) laser surgery for extensive, cauliflower-like anogenital condylomata acuminata: retrospective long-term study on 19 HIV-positive and 45 HIV-negative men. Dermatology 2002, 205:255-259.
18. Abeer A, Ayman M. Pulsed dye laser versus podophyllin resin in treatment of female genital warts. Egypt Dermatol Online J 2007, 3:5.
19. Badawi A, Shokeir HA, Salem AM. Treatment of genital warts in males by pulsed dye laser. J Cosmet Laser Ther 2006, 8:92-95.
20. Gross G, Rogozinski T, Schöfer H. Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients. Dermatology 1998, 196:330-334.
21. Veregen: a botanical for treatment of genital warts. Med Lett Drugs Ther 2008, 50:15-16.
22. Coremans G, Margaritis V, Snoeck R. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. Dis Colon Rectum 2003, 46:1103-1108.
23. Muñoz N, Bosch FX, de Sanjosé S. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
24. Hung CF, Ma B, Monie A. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008, 8:421-439.
25. Villa LL, Costa RL, Petta CA. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
26. Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis 2007, 11(Suppl 2):S17-S25.
27. Urman CO, Gottlieb AB. New viral vaccines for dermatologic disease. J Am Acad Dermatol 2008, 58:361-370.
28. Harper DM, Franco EL, Wheeler C. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
29. Lazarczyk M, Pons C, Mendoza JA. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008, 205:35-42.
30. Lazarczyk M, Cassonnet P, Pons C. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009, 73:348-370.
31. Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 2007, 23:247-259.
32. Berk DR, Bruckner AL, Lu D. Epidermodysplasia verruciform-like lesions in an HIV patient. Dermatol Online J 2009, 15:1.
33. Gewirtzman A, Bartlett B, Tyring S. Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis 2008, 21:141-146.
34. Haas N, Fuchs PG, Hermes B. Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient. Br J Dermatol 2001, 145:669-670.
35. Chen P, Kamino H, Walters RF. Epidermodysplasia verruciformis in the setting of HIV infection. Dermatol Online J 2008, 14:1.
36. Hogewoning CJA, Bleeker MCG, van den Brule AJC. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003, 107:811-816.
37. De Panfilis G, Melzani G, Mori G. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transmit Dis 2002, 29:121-125.
38. Silverberg MJ, Ahdieh L, Munoz A. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transmit Dis 2002, 29:427-435.
39. Silverberg MJ, Thorsen P, Lindeberg H. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003, 101:645-652.
40. Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999, 12:1-8.
41. Mertz GJ, Benedetti J, Ashley R. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992, 116:197-202.
42. Wald A, Zeh J, Selke S. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995, 333:770-775.
43. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000, 45(Suppl T3):1-8.
44. Sexually Transmitted Diseases Treatment Guidelines 2006. Department of Health and Human Services. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov/std/treatment/2006/genital-ulcers.htm, Available at: Accessed June 19, 2009
45. Wald A, Carrell D, Remington M. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002, 34:944-948.
46. Aoki FY, Tyring S, Diaz-Mitoma F. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006, 42:8-13.
47. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002, 34:958-962.
48. Chosidow O, Drouault Y, Leconte-Veyriac F. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001, 144:818-824.
49. Bodsworth NJ, Crooks RJ, Borelli S. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 1997, 73:110-116.
50. Patel R, Bodsworth NJ, Woolley P. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med 1997, 73:105-109.
51. Fife KH, Barbarash RA, Rudolph T. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997, 24:481-486.
52. Diaz-Mitoma F, Sibbald RG, Shafran SD. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA 1998, 280:887-892.
53. Mertz GJ, Loveless MO, Levin MJ. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997, 157:343-349.
54. Romanowski B, Marina RB, Roberts JN. Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003, 30:226-231.
55. Patel R, Rutland E. Has episodic treatment of recurrent genital herpes come of age? Int J STD AIDS 2007, 18:437-439.
56. Corey L, Wald A, Patel R. Valacyclovir HSV Transmission Study Group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
57. Fife KH, Almekinder J, Ofner S. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis 2007, 34:297-301.
58. Strand A, Patel R, Wulf HC. International Valaciclovir HSV Study Group. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002, 78:435-439.
59. Miller RL, Imbertson LM, Reiter MJ. Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Res 1999, 44:31-42.
60. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001, 137:1015-1017.
61. Danielsen AG, Petersen CS, Iversen J. Chronic erosive herpes simplex virus infection of the penis in a human immunodeficiency virus positive man, treated with imiquimod and famciclovir. Br J Dermatol 2002, 147:1034-1036.
62. Christensen B, Hengge UR. Recurrent urogenital herpes simplex successful treatment with imiquimod? Sex Transm Infect 1999, 75:132-133.
63. Martinez V, Molina JM, Scieux C. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 2006, 119:e9-e11.
64. Weeratna RD, Makinen SR, McCluskie MJ. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine 2005, 23:5263-5270.
65. Schacker TW, Conant M, Thoming C. The Imiquimod HSV study group. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2002, 46:3243-3248.
66. Fife KH, Meng TC, Ferris DG. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. Antimicrob Agents Chemother 2008, 52:477-482.
67. Mark KE, Corey L, Meng TC. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007, 195:1324-1331.
68. Overall JC, Yeh TJ, Kern ER. Sensitivity of herpes simplex virus types 1 and 2 to three preparations of human interferon. J Infect Dis 1980, 142:943.
69. Kuhls TL, Sacher J, Pineda E. Suppression of recurrent genital herpes simplex virus infection with recombinant alpha 2 interferon. J Infect Dis 1986, 154:437-442.
70. Lebwohl M, Sacks S, Conant M. Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. Antiviral Res 1992, 17:235-243.
71. Glezerman M, Lunenfeld E, Cohen V. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet 1988, 1:150-152.
72. Vonka V, Petrovská P, Borecký L. Increased effects of topically applied interferon on herpes simplex virus-induced lesions by caffeine. Acta Virol 1995, 39:125-130.
73. Shupack J, Stiller M, Knobler E. Topical alpha-interferon in recurrent genital herpes simplex infection. A double-blind, placebo-controlled clinical trial. Dermatologica 1990, 181:134-138.
74. An expanded phase i randomized placebo controlled trial of the safety and tolerability of 3% w/w SPL7013 gel (VivaGel™) in healthy young women when administered twice daily for 14 days. http://www.starpharma.com/data/080512%20Starpharma%20reports%20positive%20VivaGel%20clinical%20study%20results.pdf, Clinical Trial Results Appendix - Study No. SPL7013-004. ClinicalTrials.gov identifier: NCT00331032. Available at: Accessed on June 19, 2009
75. Keller MJ, Tuyama A, Carlucci MJ. Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 2005, 55:420-423.
76. Keller MJ, Zerhouni-Layachi B, Cheshenko N. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006, 193:27-35.
77. Hemmi H, Takeuchi O, Kawai T. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
78. Ashkar AA, Bauer S, Mitchell WJ. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 2003, 77:8948-8956.
79. Sajic D, Ashkar AA, Patrick AJ. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol 2003, 71:561-568.
80. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003, 77:953-962.
81. Pyles RB, Higgins D, Chalk C. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 2002, 76:11387-11396.
82. McCluskie MJ, Cartier JL, Patrick AJ. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res 2006, 69:77-85.
83. Herbst MM, Pyles RB. Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother 2003, 52:887-889.
84. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004, 11:437-445.
85. Langenberg AG, Burke RL, Adair SF. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 1995, 122:889-898.
86. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004, 11(Suppl 3):161A-169A.
87. Stanberry LR, Spruance SL, Cunningham AL. GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661.
88. Mertz GJ, Ashley R, Burke RL. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990, 161:653-660.
89. Frank SB. Formolized herpes virus therapy and the neutralizing substance in herpes simplex. J Invest Dermatol 1938, 1:267-282.
90. Dundarov S, Andonov P, Bakalov B. Immunotherapy with inactivated polyvalent herpes vaccines. Dev Biol Stand 1982, 52:351-358.
91. Kern AB, Schiff BL. Vaccine therapy in recurrent herpes simplex. Arch Dermatol 1964, 89:844-845.
92. Schmersahl P, Rüdiger G. Results of treatment with the Herpes simplex antigen Lupidon H, resp. Lupidon G. Z Hautkr 1975, 50:105-112.
93. Mastrolorenzo A, Tiradritti L, Salimbeni L. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection. Int J STD AIDS 1995, 6:431-435.
94. Weitgasser H. Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G. Z Hautkr 1977, 52:625-628.
95. Cappel R, Sprecher S, De Cuyper F. Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol 1985, 16:137-145.
96. Skinner GR, Woodman C, Hartley C. Early experience with " antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis. Dev Biol Stand 1982, 52:333-344.
97. Woodman CB, Buchan A, Fuller A. Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis. Br J Vener Dis 1983, 59:311-313.
98. Skinner GR, Turyk ME, Benson CA. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol 1997, 186:31-36.
99. Straus SE, Savarese B, Tigges M. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993, 167:1045-1052.
100. Straus SE, Corey L, Burke RL. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343:1460-1463.
101. Straus SE, Wald A, Kost RG. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176:1129-1134.
102. Wachsman M, Kulka M, Smith CC. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 2001, 16:1879-1890.
103. Casanova G, Cancela R, Alonzo L. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002, 70:235-239.
104. Wald A, Langenberg AG, Krantz E. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005, 143:707-713.
105. Briefing document for the antiviral drugs advisory committee. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B2_01_GlaxoSmithKline-Valtrex.pdf, May 14, 2003. Available at: Accessed on June 19, 2009
106. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007, 370:2127-2137.
107. Wald A, Langenberg AG, Link K. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001, 285:3100-3106.
108. Romanowski B, Aoki FY, Martel AY. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS 2000, 14:1211-1217.
109. Conant MA, Schacker TW, Murphy RL. International Valaciclovir HSV Study Group. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002, 13:12-21.
110. DeJesus E, Wald A, Warren T. Valacyclovir International HSV Study Group. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003, 188:1009-1016.
111. Posavad CM, Wald A, Kuntz S. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004, 190:693-696.
112. Stone KM, Reiff-Eldridge R, White AD. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004, 70:201-207.
113. Sheffield JS, Hollier LM, Hill JB. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003, 102:1396-1403.
114. Watts DH, Brown ZA, Money D. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003, 188:836-843.
115. Scott LL, Hollier LM, McIntire D. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002, 10:71-77.
116. Schöfer H, Van Ophoven A, Henke U. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006, 16:642-648.
117. Arican O, Guneri F, Bilgic K. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 2004, 31:627-631.
118. Edwards L, Ferenczy A, Eron L. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998, 134:25-30.
119. Simmons PD, Langlet F, Thin RN. Cryotherapy versus electrocautery in the treatment of genital warts. Br J Vener Dis 1981, 57:273-274.
120. White DJ, Billingham C, Chapman S. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study. Genitourin Med 1997, 73:184-187.
121. Beutner KR, Conant MA, Friedman-Kien AE. Patient-applied podofilox for treatment of genital warts. Lancet 1989, 1:831-834.
122. Bonnez W, Elswick RK, Bailey-Farchione A. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med 1994, 96:420-425.
123. Greenberg MD, Rutledge LH, Reid R. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991, 77:735-739.
124. Kirby P, Dunne A, King DH. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990, 88:465-469.
125. Tyring S, Edwards L, Cherry LK. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998, 134:33-38.
126. Syed TA, Lundin S, Ahmad SA. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study. Dermatology 1994, 189:142-145.
127. Lacey CJ, Goodall RL, Tennvall GR. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003, 79:270-275.
128. Lassus A. Comparison of podophyllotoxin and podophyllin in treatment of genital warts. Lancet 1987, 2:512-513.
129. Eron LJ, Alder MB, O'Rourke JM. Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon. Genitourin Med 1993, 69:91-93.
130. Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993, 20:344-345.
131. Damstra RJ, van Vloten WA. Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. J Dermatol Surg Oncol 1991, 17:273-276.
132. Godley MJ, Bradbeer CS, Gellan M. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med 1987, 63:390-392.
133. Stone KM, Becker TM, Hadgu A. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990, 66:16-19.
134. Duus BR, Philipsen T, Christensen JD. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med 1985, 61:59-61.
135. Frega A, Baiocco E, Pace S. Regression rate of clinical HPV infection of the lower genital tract during pregnancy after laser CO2 surgery. Clin Exp Obstet Gynecol 2006, 33:93-95.
136. Petersen CS, Bjerring P, Larsen J. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991, 67:99-102.
137. Schwartz DB, Greenberg MD, Daoud Y. Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol 1988, 158:1407-1416.
138. Reichman RC, Oakes D, Bonnez W. Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. Ann Intern Med 1988, 108:675-679.
139. Benedetti Panici P, Scambia G. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol 1989, 74:393-397.
140. Bornstein J, Pascal B, Zarfati D. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int J STD AIDS 1997, 8:614-621.
141. Tatti S, Swinehart JM, Thielert C. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008, 111:1371-1379.
142. Garland SM, Hernandez-Avila M, Wheeler CM. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
143. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
144. Villa LL, Costa RL, Petta CA. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
145. Herrero R, Hildesheim A, Rodríguez AC. Costa Rica Vaccine Trial (CVT) Group. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26:4795-4808.
146. Bavaro JB, Drolette L, Koelle DM. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis 2008, 35:383-386.
147. Baker DA. Long-term suppressive therapy with acyclovir for recurrent genital herpes. J Int Med Res 1994, 22(Suppl 1):24A-31A. discussion 31A-32A
148. Blom I, Back O, Egelrud T. Long-term oral acyclovir treatment prevents recurrent genital herpes. Dermatologica 1986, 173:220-223.
149. Braig S, Luton D, Sibony O. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol 2001, 96:55-58.
150. Bryson YJ. Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus. J Antimicrob Chemother 1983, 12(Suppl B):61-65.
151. Bryson YJ, Dillon M, Lovett M. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983, 308:916-921.
152. Douglas JM, Critchlow C, Benedetti J. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984, 310:1551-1556.
153. Fiddian AP, Halsos AM, Kinge BR. Oral acyclovir in the treatment of genital herpes. preliminary report of a multicenter trial. Am J Med 1982, 73:335-337.
154. Goldberg LH, Kaufman R, Kurtz TO. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. acyclovir study group. Arch Dermatol 1993, 129:582-587.
155. Goldberg LH, Kaufman RH, Kurtz TO. Continuous five-year treatment of patients with frequently recurring genital herpes simplex virus infection with acyclovir. J Med Virol 1993, (Suppl 1):45-50.
156. Gupta R, Wald A, Krantz E. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004, 190:1374-1381.
157. Halsos AM, Salo OP, Lassus A. Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study. Acta Derm Venereol 1985, 65:59-63.
158. Kaplowitz LG, Baker D, Gelb L. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. the acyclovir study group. JAMA 1991, 265:747-751.
159. Kinghorn GR, Jeavons M, Rowland M. Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study. Genitourin Med 1985, 61:387-390.
160. Kroon S, Petersen CS, Andersen LP. Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double-blind, placebo-controlled cross-over study. Dan Med Bull 1989, 36:298-300.
161. Mertz GJ, Critchlow CW, Benedetti J. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA 1984, 252:1147-1151.
162. Mertz GJ, Jones CC, Mills J. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988, 260:201-206.
163. Mindel A, Faherty A, Carney O. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988, 1:926-928.
164. Mindel A, Weller IV, Faherty A. Prophylactic oral acyclovir in recurrent genital herpes. Lancet 1984, 2:57-59.
165. Nilsen AE, Aasen T, Halsos AM. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982, 2:571-573.
166. Reichman RC, Badger GJ, Mertz GJ. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984, 251:2103-2107.
167. Reichman RC, Ginsberg M, Barrett-Connor E. Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary report. Am J Med 1982, 73:338-341.
168. Ruhnek-Forsbeck M, Sandstrom E, Andersson B. Treatment of recurrent genital herpes simplex infections with oral acyclovir. J Antimicrob Chemother 1985, 16:621-628.
169. Sacks SL, Fox R, Levendusky P. Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes. Sex Transm Dis 1988, 15:58-62.
170. Straus SE, Takiff HE, Seidlin M. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984, 310:1545-1550.
171. Thin RN, Jeffries DJ, Taylor PK. Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial. J Antimicrob Chemother 1985, 16:219-226.
172. Velasco M, Saavedra T, Sepulveda C, Suarez M. Prolonged treatment with acyclovir in recurrent genital herpes. clinical, virological, and immunological response. Rev Med Chil 1991, 119:876-880.
173. Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J Infect Dis 2004, 189:1341-1347.
174. Sacks SL, Aoki FY, Diaz-Mitoma F. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. canadian famciclovir study group. JAMA 1996, 276:44-49.
175. Sacks SL, Aoki FY, Martel AY. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin Infect Dis 2005, 41:1097-1104.
176. Tyring S, Berger T, Yen-Moore A. Single-day therapy for recurrent genital herpes. Am J Clin Dermatol 2006, 7:209-211.
177. Tyring SK, Diaz-Mitoma F, Shafran SD. Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials. J Cutan Med Surg 2003, 7:449-454.
178. Andrews WW, Kimberlin DF, Whitley R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol 2006, 194:774-781.
179. Fife KH, Warren TJ, Ferrera RD. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006, 81:1321-1327.
180. Fife KH, Warren TJ, Justus SE. HS2100275 STUDY TEAM. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Sex Transm Dis 2008, 35:668-673.
181. Handsfield HH, Warren T, Werner M. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life. Sex Transm Dis 2007, 34:339-343.
182. Nagot N, Ouedraogo A, Foulongne V. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790-799.
183. Reitano M, Tyring S, Lang W. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. international valaciclovir HSV study group. J Infect Dis 1998, 178:603-610.
184. Sheffield JS, Hill JB, Hollier LM. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol 2006, 108:141-147.
185. Spruance SL, Tyring SK, DeGregorio B. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. valaciclovir HSV study group. Arch Intern Med 1996, 156:1729-1735.
186. Barton IG, Kinghorn GR, Rowland M. Recurrences after first episodes of genital herpes in patients treated with topical acyclovir cream. Antiviral Res 1984, 4:293-300.
187. Corey L, Nahmias AJ, Guinan ME. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med 1982, 306:1313-1319.
188. Corey L, Benedetti JK, Critchlow CW. Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. Am J Med 1982, 73:326-334.
189. Corey L, Benedetti J, Critchlow C. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983, 12(Suppl B):79-88.
190. Fiddian AP, Kinghorn GR, Goldmeier D. Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy. J Antimicrob Chemother 1983, 12(Suppl B):67-77.
191. Kinghorn GR, Abeywickreme I, Jeavons M. Efficacy of combined treatment with oral and topical acyclovir in first episode genital herpes. Genitourin Med 1986, 62:186-188.
192. Laerum E, Gabrielsen BO, Halsos A. Acyclovir creme in recurrent herpes genitalis. Tidsskr Nor Laegeforen 1989, 109:847-849.
193. Thin RN, Nabarro JM, Parker JD. Topical acyclovir in the treatment of initial genital herpes. Br J Vener Dis 1983, 59:116-119.
194. Mendelson J, Clecner B, Eiley S. Effect of recombinant interferon alpha 2 on clinical course of first episode genital herpes infection and subsequent recurrences. Genitourin Med 1986, 62:97-101.
195. Sacks SL, Varner TL, Davies KS. Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes. J Infect Dis 1990, 161:692-698.
196. Syed TA, Cheema KM, Kahlon BM. Human leukocyte interferon-alpha in cream for the treatment of genital herpes in Asian males. A placebo-controlled, double-blind study. Dermatology 1995, 191:32-35.
197. Syed TA, Ahmadpour OA, Ahmad SA. Human leukocyte interferon-alpha in a hydrophilic cream versus in a gel for the treatment of genital herpes in males: a placebo-controlled, double-blind, comparative study. J Dermatol 1997, 24:564-568.
198. Ahumada M. The effectiveness of tromantadine in herpes simplex: double-blind study. Ther Ggw 1977, 116:100-108.
199. Altomare GF, Polenghi MM, Pigatto PD. Tromantadine hydrochloride in the treatment of herpes genitalis. A double-blind controlled study. G Ital Dermatol Venereol 1985, 120:XLI-XLVI.
200. Petersen CS, Weismann K, Avnstorp C. Topical tromantadine in the treatment of genital herpes. A double-blind placebo controlled study. Dan Med Bull 1993, 40:506-507.
201. Lalezari J, Schacker T, Feinberg J. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997, 176:892-898.
202. Sacks SL, Shafran SD, Diaz-Mitoma F. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother 1998, 42:2996-2999.
203. Parker JD. A double-blind trial of idoxuridine in recurrent genital herpes. J Antimicrob Chemother 1977, 3(Suppl A):131-137.
204. Silvestri DL, Corey L, Holmes KK. Ineffectiveness of topical idoxuridine in dimethyl sulfoxide for therapy for genital herpes. JAMA 1982, 248:953-959.
205. Glezerman M, Lunenfeld E, Doerner T. Beta-interferon for labial and genital herpes virus infection. Harefuah 1989, 116:88-90.
206. Chen XS, Han GZ, Guo ZP. Penciclovir Multicenter Genital Herpes Clinical Study Group. A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicentre trial. Int J STD AIDS 2000, 11:568-573.